Welcome to our dedicated page for GMDA news (Ticker: GMDA), a resource for investors and traders seeking the latest updates and insights on GMDA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GMDA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GMDA's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Gamida Cell Ltd. (Nasdaq: GMDA) announced the pricing of a public offering of 17,500,000 ordinary shares along with warrants for gross proceeds of approximately $22.8 million at a price of $1.30 per share. The warrants, with an exercise price of $1.35, are immediately exercisable and will expire in five years. The offering closing is expected on April 21, 2023, pending customary conditions. The company plans to utilize the net proceeds for the commercialization of Omisirge®, continued development of GDA-201, and general corporate purposes. An additional 2,625,000 shares may be purchased by underwriters within 30 days of the offering. A registration statement has been filed and became effective on April 1, 2022.
Gamida Cell Ltd. (Nasdaq: GMDA) announced a follow-on public offering of its ordinary shares and accompanying warrants, with the potential for underwriters to purchase an additional 15%. The offering is contingent on market conditions, and no completion guarantee is provided. Proceeds will support commercial activities for Omisirge®, continued clinical development of GDA-201, and general corporate purposes. The registration statement for the shares was previously filed and became effective on April 1, 2022. The offering is managed by Piper Sandler & Co..
Gamida Cell Ltd. announces FDA approval of Omisirge (omidubicel-onlv), an allogeneic cell therapy for adult and pediatric patients 12 years and older with hematologic malignancies. This approval is based on a global randomized Phase 3 clinical trial demonstrating significant benefits, including a median time to neutrophil recovery of 12 days versus 22 days for standard cord blood (p<0.001). Furthermore, Omisirge showed a reduced incidence of severe infections (39% vs. 60%). With breakthrough therapy designation and orphan drug designation, Omisirge potentially increases access to transplants, particularly for racially diverse patients. The company is actively onboarding transplant centers and pursuing strategic partnerships for commercialization. A conference call is scheduled for April 18 at 8 am ET.
